ALDR Alder BioPharmaceuticals Inc.

11.65
-0.45  -4%
Previous Close 12.10
Open 12.15
Price To book 3.60
Market Cap 788863824
Shares 67,713,633
Volume 1,133,076
Short Ratio 4.10
Av. Daily Volume 1,304,357

SEC filingsSee all SEC filings

  1. 8-K - Current report 171084839
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019930
  3. 8-K - Current report 171014890
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014622
  5. 8-K - Current report 17964490

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 PROMISE 2 enrollment to be completed 2H 2017.
ALD403 - PROMISE 2
Frequent episodic migraine
Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403
Chronic Migraine
Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised.
ALD403 - PROMISE 1
Frequent episodic migraine

Latest News

  1. See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.
  2. ETFs with exposure to Alder Biopharmaceuticals, Inc. : October 6, 2017
  3. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : September 19, 2017
  4. What Does Alder Biopharmaceuticals Inc’s (ALDR) Share Price Indicate?
  5. ETFs with exposure to Alder Biopharmaceuticals, Inc. : September 12, 2017
  6. Alder BioPharmaceuticals® to Present Data from Eptinezumab Development Program at 18th Congress of the International Headache Society
  7. Alder BioPharmaceuticals® to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
  8. ETFs with exposure to Alder Biopharmaceuticals, Inc. : August 31, 2017
  9. Biotech Stocks To Watch And Pharma Industry News
  10. [$$] Down With Teva, Up With Portola
  11. Alder Biopharmaceuticals, Inc. :ALDR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  12. Edited Transcript of ALDR earnings conference call or presentation 8-Aug-17 9:00pm GMT
  13. Alder BioPharmaceuticals posts 2Q loss
  14. Alder BioPharmaceuticals® Announces Second Quarter 2017 Financial and Operating Results
  15. Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results
  16. DELTA DRONE : Six-month report on the liquidity agreement with Louis Capital Markets

SEC Filings

  1. 8-K - Current report 171084839
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019930
  3. 8-K - Current report 171014890
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014622
  5. 8-K - Current report 17964490
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17962664
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17960610
  8. 8-K - Current report 17943199
  9. 8-K - Current report 17909624
  10. 8-K - Current report 17874903